InformedDNA Secures Growth Investment from TT Capital Partners, NovaQuest and Frist Cressey Ventures
December 13, 2019
InformedDNA, the U.S. leader in genetics services, has entered definitive agreements with TT Capital Partners, NovaQuest Capital Management, and Frist Cressey Ventures to receive a growth capital investment to scale its technology-enabled genetic services and expand its genetic counseling staff. Terms were not disclosed; InformedDNA will remain led by CEO David Nixon and has also secured a flexible credit facility from CIBC.
- Buyers
- TT Capital Partners, NovaQuest Capital Management, Frist Cressey Ventures
- Targets
- InformedDNA
- Industry
- Healthcare Services
- Location
- Florida, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
InformedDNA Acquires gWell Health
September 21, 2023
Healthcare Services
InformedDNA has acquired gWell Health, a digital health and genomics-driven wellness platform, and appointed gWell founder Surya Singh, MD as InformedDNA's CEO. The deal will combine InformedDNA's clinical genomics expertise with gWell's technology to expand precision-health offerings across prevention, musculoskeletal care, oncology, drug metabolism and maternity care; financial terms were not disclosed.
-
Fulgent Genetics Acquires Inform Diagnostics from Avista Capital Partners
April 18, 2022
Healthcare Services
Fulgent Genetics agreed to acquire Inform Diagnostics, a leading national independent pathology laboratory headquartered in Irving, Texas, for approximately $170 million. The acquisition from Avista Capital Partners expands Fulgent’s pathology and anatomic testing menu, adds nationwide commercial and managed-care relationships, and broadens its geographic lab footprint to support cross-selling of genomic and pathology services.
-
Praesidian Capital Acquires Undisclosed Genetics Business
September 18, 2019
Healthcare Services
Praesidian Capital announced the acquisition of an integrated clinical and laboratory services company operating in genetic medicine, focused on prenatal and preconception testing and hereditary cancer risk assessments. The deal is Praesidian’s first as an independent sponsor and will serve as a platform for national expansion and future add-on acquisitions.
-
OncoCyte Corporation Acquires Insight Genetics
January 10, 2020
Healthcare Services
OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.
-
Ampersand Capital Partners Completes Growth Equity Investment in GenDx
May 8, 2019
Biotechnology
Ampersand Capital Partners completed a minority growth equity investment in Genome Diagnostics B.V. (GenDx), a Utrecht-based provider of molecular diagnostic kits and analysis software for transplantation and companion diagnostics. The partnership will support GenDx's organic growth and M&A strategy; Ampersand's David Parker and Operating Partner Mike Evans joined GenDx's board.
-
Novo Holdings Leads $50M Growth Investment in MedGenome
August 30, 2022
Biotechnology
Novo Holdings led a $50 million minority investment in MedGenome alongside existing investors LeapFrog Investments and Sofina. The capital will support MedGenome’s expansion beyond South Asia into Africa and the Middle East and broaden access to its genomic testing, bioinformatics and research services.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.